Related Experiment Video

Updated: May 8, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Identification of micro-RNA networks in end-stage heart failure because of dilated cardiomyopathy

Xiaoming Zhu1, Hongjiang Wang, Fan Liu

  • 1Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Journal of Cellular and Molecular Medicine
|September 4, 2013
PubMed

Insights

MicroRNAs regulate gene expression. This study identified miR-340 as a key microRNA involved in heart failure progression, offering potential new therapeutic targets for this condition.

Area of Science:

  • Cardiovascular Biology
  • Molecular Genetics
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are crucial regulators of gene expression, influencing cellular processes.
  • Dysregulation of miRNA expression is implicated in various pathological conditions, including heart failure.
  • Understanding miRNA roles in cardiac pathophysiology is vital for developing targeted therapies.

Purpose of the Study:

  • To profile miRNA expression in human failing hearts and identify key miRNAs contributing to heart failure.
  • To elucidate the molecular signaling networks regulated by these miRNAs in cardiac disease.
  • To investigate the specific role of identified miRNAs, particularly miR-340, in the progression of heart failure.

Main Methods:

  • Analysis of miRNA and gene expression profiles in myocardial biopsy samples from heart failure patients and normal controls.
  • Construction of integrated gene regulatory, signal-network, miRNA-GO-network, and miRNA-gene-network models.
  • Validation of differentially expressed miRNAs using quantitative reverse transcription PCR (RT-PCR).
  • In vitro overexpression of miR-340 in neonatal rat cardiomyocytes to assess its functional impact.

Main Results:

  • Comprehensive miRNA expression profiling revealed significant alterations in end-stage heart failure.
  • miR-340 was identified as a significantly dysregulated miRNA in cardiac pathophysiology.
  • Overexpression of miR-340 in cardiomyocytes led to increased expression of cardiac stress markers (ANP, BNP) and apoptosis (caspase-3).
  • miR-340 overexpression resulted in a significant increase in cardiomyocyte size, indicating hypertrophic changes.

Conclusions:

  • This study provides a detailed miRNA expression profile in end-stage human heart failure.
  • miR-340 is identified as a critical miRNA involved in the development and progression of heart failure.
  • miR-340 represents a promising novel therapeutic target for heart failure treatment.
Keywords:
heart failuremicroRNAsnetwork

More Related Videos

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...